<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stevens-Johnson syndrome/toxic epidermal necrolysis: Pharmacogenetic associations in different populations</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stevens-Johnson syndrome/toxic epidermal necrolysis: Pharmacogenetic associations in different populations</h1>
<div class="graphic"><div class="figure"><div class="ttl">Stevens-Johnson syndrome/toxic epidermal necrolysis: Pharmacogenetic associations in different populations</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1_left">Associated drug</td> <td class="subtitle1_left">HLA allele</td> <td class="subtitle1_left">Population</td> </tr> <tr> <td rowspan="4">Carbamazepine</td> <td>B*1502</td> <td>Han Chinese, Thai, Malaysian, Singaporean, Indian, Japanese, <span class="nowrap_whitespace">Korean<sup>[1-7]</sup></span></td> </tr> <tr> <td>B*1511</td> <td>Han Chinese, Japanese, <span class="nowrap_whitespace">Korean<sup>[8-9]</sup></span></td> </tr> <tr> <td>B*5701</td> <td>European<sup>[10]</sup></td> </tr> <tr> <td>A*31:01 (for DRESS and SJS/TEN)</td> <td>European, Japanese, <span class="nowrap_whitespace">Korean<sup>[11-13]</sup></span></td> </tr> <tr class="highlight_lght_gray_text"> <td>Oxcarbazepine</td> <td>B*1502</td> <td>Han Chinese, Thai<sup>[14]</sup></td> </tr> <tr> <td>Allopurinol</td> <td>B*5801</td> <td> <p>Han Chinese<sup>[15]</sup></p> <p>European<sup>[16]</sup></p> <p>Japanese<sup>[17]</sup></p> <p>Thai<sup>[18]</sup></p> Korean<sup>[19]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="6">Phenytoin</td> <td>B*15:02</td> <td>Han Chinese, Thai, Malaysian<sup>[20]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>B*13:01</td> <td>East Asian<sup>[21]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>B*51:01</td> <td>East Asian<sup>[22]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>B*38:02</td> <td>Thai<sup>[23]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>B*15:13</td> <td>Malaysian<sup>[24]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>CYP2C9*3</td> <td>Han Chinese, Japanese, Malaysian, Thai<sup>[25]</sup></td> </tr> <tr> <td rowspan="3">Lamotrigine</td> <td>B*15:02</td> <td>Han Chinese, Thai<sup>[20]</sup></td> </tr> <tr> <td>B*38</td> <td>European<sup>[10]</sup></td> </tr> <tr> <td>HLA-A*31:01</td> <td>Korean<sup>[26]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>Dapsone</td> <td>B*13:01</td> <td>Southeast Asian<sup>[27]</sup></td> </tr> <tr> <td rowspan="4">Sulfamethoxazole</td> <td> <p>A*29</p> B*38</td> <td>European<sup>[10]</sup></td> </tr> <tr> <td>B*15:02</td> <td>Thai<sup>[28]</sup></td> </tr> <tr> <td>C*06-02</td> <td>Thai<sup>[28,29]</sup></td> </tr> <tr> <td>C*08:01</td> <td>Thai<sup>[30]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>Methazolamide</td> <td>B*59:01</td> <td>Korean/Japanese/Han Chinese<sup>[31]</sup></td> </tr> <tr> <td>Oxicam NSAIDs</td> <td>B*73</td> <td>European<sup>[10]</sup></td> </tr> <tr class="highlight_lght_gray_text"> <td>Nevirapine</td> <td>C*04-01</td> <td>Malawian<sup>[32]</sup></td> </tr> <tr> <td>Strontium ranelate</td> <td>A*33:03</td> <td>Han Chinese<sup>[33,34]</sup></td> </tr> </tbody></table></div><div class="graphic_footnotes">DRESS: drug reaction with eosinophilia and systemic symptoms; HLA: human leukocyte antigen; NSAID: nonsteroidal anti-inflammatory drug; SJS: Stevens-Johnson syndrome; TEN: toxic epidermal necrolysis.</div><div class="graphic_reference">References:
<ol>
<li>Chung WH, Hung SI, Hong HS, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature 2004; 428:486.</li>
<li>Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, et al. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. JAMA Dermatol 2013; 149:1025.</li>
<li>Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015.</li>
<li>Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49:2087.</li>
<li>Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75:579.</li>
<li>Kwan PK, Ng MH, Lo SV. Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: A population-based study. Hong Kong Med J 2014; 20 Suppl 7:16.</li>
<li>Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011; 50:221.</li>
<li>Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010; 51:2461.</li>
<li>Sun D, Yu CH, Liu ZS, et al. Association of HLA-B*1502 and *1511 allele with antiepileptic drug-induced Stevens-Johnson syndrome in central China. J Huazhong Univ Sci Technolog Med Sci 2014; 34:146.</li>
<li>Mockenhaupt M, Wang CW, Hung SI, et al. HLA-B*57:01 confers genetic susceptibility to carbamazepine-induced SJS/TEN in Europeans. Allergy 2019; 74:2227.</li>
<li>Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034.</li>
<li>McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.</li>
<li>Kim SH, Lee KW, Song WJ, et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res 2011; 97:190.</li>
<li>Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 2017; 88:78.</li>
<li>Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.</li>
<li>Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99.</li>
<li>Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617.</li>
<li>Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19:704.</li>
<li>Kang HR, Jee YK, Kim YS, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011; 21:303.</li>
<li>Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11:349.</li>
<li>Su SC, Chen CB, Chang WC, et al. HLA alleles and CYP2C9*3 as predictors of phenytoin hypersensitivity in East Asians. Clin Pharmacol Ther 2019; 105:476.</li>
<li>John S, Balakrishnan K, Sukasem C, et al. Association of HLA-B*51:01, HLA-B*55:01, CYP2C9*3, and phenytoin-induced cutaneous adverse drug reactions in the South Indian Tamil Population. J Pers Med 2021; 11:737.</li>
<li>Manuyakorn W, Likkasittipan P, Wattanapokayakit S, et al. Association of HLA genotypes with phenytoin induced severe cutaneous adverse drug reactions in Thai children. Epilepsy Res 2020; 162:106321.</li>
<li>Chang CC, Ng CC, Too CL, et al. Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population. Pharmacogenomics J 2017; 17:170.</li>
<li>Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014; 312:525.</li>
<li>Kim BK, Jung JW, Kim TB, et al. HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population. Ann Allergy Asthma Immunol 2017; 118:629.</li>
<li>Tempark T, Satapornpong P, Rerknimitr P, et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. Pharmacogenet Genomics 2017; 27:429.</li>
<li>Sukasem C, Pratoomwun J, Satapornpong P, et al. Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific: HLA class I genotypes and haplotypes. Clin Pharmacol Ther 2020; 108:1078.</li>
<li>Nakkam N, Saksit N, Konyoung P, et al. Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions. Drug Metab Pharmacokinet 2022; 47:100480.</li>
<li>Kongpan T, Mahasirimongkol S, Konyoung P, et al. Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics 2015; 25:402.</li>
<li>Kim SH, Kim M, Lee KW, et al. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics 2010; 11:879.</li>
<li>Carr DF, Chaponda M, Jorgensen AL, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis 2013; 56:1330.</li>
<li>Lee HY, Shen MX, Lim YL, et al. Increased risk of strontium ranelate-related SJS/TEN is associated with HLA. Osteoporos Int 2016; 27:2577.</li>
<li>Chen CB, Chen YE, Chu MT, et al. The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. J Eur Acad Dermatol Venereol 2021; 35:712.</li>
</ol></div><div id="graphicVersion">Graphic 142089 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
